Over the last decade, there has been increasing concern regarding disruption of endocrine and reproductive systems as a consequence of in utero exposure to xenobiotics. Key to preventing these responses is identification of cellular mechanisms that regulate prenatal disposition of endocrine disrupting chemicals (EDCs). One potential way to reduce levels of EDCs in the fetus is to transport them across the placenta back to the maternal circulation. One prominent transporter, breast cancer resistance protein (BCRP), has been shown to participate in the placental transfer of chemicals. Recent data from this laboratory demonstrate that the model EDC, the phytoestrogen genistein, is a BCRP substrate, and that various EDCs inhibit BCRP transport. We hypothesize that BCRP maintains low concentrations of EDCs in the fetal compartment by actively transporting them back to the maternal circulation. This is important because impaired BCRP function would increase fetal levels of EDCs and enhance disruption of reproductive development. This hypothesis will be tested using a combination of in vitro and in vivo approaches that evaluate BCRP transport of EDCs and identify the regulatory mechanisms that influence BCRP expression and activity in human placenta. We anticipate that EDCs will be BCRP substrates and that reduced Bcrp transporter function will increase EDC levels in mouse fetuses. Further, it is expected that Bcrp-null offspring will have more profound abnormalities in reproductive and mammary gland development following prenatal genistein exposure, compared to wild-types. These studies will fill significant knowledge gaps in the fields of placental transport and fetal susceptibility to environmental toxicants. The proposed research is critically needed because multiple sources of EDCs exist in our environment and exposure to EDCs has been documented in pregnant women. A detailed understanding of the regulation of placental BCRP will allow us to predict which patients are at greater risk for adverse effects of EDCs.
The mechanism by which the placenta removes toxic chemicals away from the fetus is poorly understood. These studies will determine whether the placental transporter BCRP reduces in utero exposure to endocrine disrupting chemicals and protects the fetus from developmental abnormalities.
|George, Blessy; You, Dahea; Joy, Melanie S et al. (2017) Xenobiotic transporters and kidney injury. Adv Drug Deliv Rev 116:73-91|
|Szilagyi, John T; Vetrano, Anna M; Laskin, Jeffrey D et al. (2017) Localization of the placental BCRP/ABCG2 transporter to lipid rafts: Role for cholesterol in mediating efflux activity. Placenta 55:29-36|
|Wen, Xia; Joy, Melanie S; Aleksunes, Lauren M (2017) In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants. Pharm Res 34:1637-1647|
|Yu, Ai-Ming; Ingelman-Sundberg, Magnus; Cherrington, Nathan J et al. (2017) Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). Acta Pharm Sin B 7:241-248|
|Francois, Lissa N; Gorczyca, Ludwik; Du, Jianyao et al. (2017) Down-regulation of the placental BCRP/ABCG2 transporter in response to hypoxia signaling. Placenta 51:57-63|
|Udasin, Ronald G; Wen, Xia; Bircsak, Kristin M et al. (2016) Nrf2 Regulates the Sensitivity of Mouse Keratinocytes to Nitrogen Mustard via Multidrug Resistance-Associated Protein 1 (Mrp1). Toxicol Sci 149:202-12|
|Bright, Amanda S; Herrera-Garcia, Guadalupe; Moscovitz, Jamie E et al. (2016) Regulation of Drug Disposition Gene Expression in Pregnant Mice with Car Receptor Activation. Nucl Receptor Res 3:|
|Moscovitz, Jamie E; Nahar, Muna S; Shalat, Stuart L et al. (2016) Correlation between Conjugated Bisphenol A Concentrations and Efflux Transporter Expression in Human Fetal Livers. Drug Metab Dispos 44:1061-5|
|Bircsak, Kristin M; Gupta, Vivek; Yuen, Poi Yu Sofia et al. (2016) Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter. J Pharmacol Exp Ther 357:103-13|
|Brunetti, Luigi; Kagan, Leonid; Forrester, Glenn et al. (2016) Cefoxitin Plasma and Subcutaneous Adipose Tissue Concentration in Patients Undergoing Sleeve Gastrectomy. Clin Ther 38:204-10|
Showing the most recent 10 out of 36 publications